semaglutide eye damage Weight loss drugs linked to higher risk of in diabetic patients | Diabetes Semaglutide Linked to Increased Risk

Researchers suspect GLP-1 may calm the guts nervous system and diminish visceral hypersensitivity , the heightened pain perception in IBS

That means no pharmacy can legally dispense FDA-approved retatrutide for weight loss in 2026

The final summary table on the report displays an Age-matched % (AM) column

Supportive regulatory approvals and inclusion in treatment guidelines are enhancing market access

retatrutide is a triple GLP-1/GIP/glucagon agonist

But in some cases, this slowing becomes excessive, leading to food sitting in the stomach for hours longer than normal, causing severe bloating, pain, and vomiting of undigested food